|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Restructuring charges | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income | |||||
| Interest income | |||||
| Interest expense | |||||
| Australian research and development incentives | |||||
| Change in fair value of embedded derivative | |||||
| Foreign currency gain (loss) | |||||
| Change in fair value of Series X preferred stock warrant liability | |||||
| Income (loss) before income taxes | |||||
| Provision for income taxes | |||||
| Net income (loss) | |||||
| Dividend attributable to down round feature of warrants | |||||
| Net income (loss) attributable to common stockholders | |||||
| Net income (loss) per share | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted average common shares outstanding | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...